Page 128 - 2019_12-Haematologica-web

C. Ciardullo et al.
31. Zanjirband M, Edmondson RJ, Lunec J. Pre-
clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget. 2016;7(26):40115-40134.
32. Herting F, Herter S, Friess T, et al. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2- selective antagonist idasanutlin (RG7388). Eur J Haematol. 2016;97(5):461-470.
33. Reis B, Jukofsky L, Chen G, et al. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica. 2016;101 (5):e185-188.
34. Esfandiari A, Hawthorne TA, Nakjang S, Lunec J. Chemical inhibition of wild-type p53-induced phosphatase 1 (WIP1/PPM1D) by GSK2830371 potentiates the sensitivity to MDM2 inhibitors in a p53-dependent manner. Mol Cancer Ther. 2016;15(3):379- 391.
35. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lympho- cytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446- 5456.
36. Pozzo F, Dal Bo M, Peragine N, et al. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro func- tional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for
clinical application. J Hematol Oncol.
2013;6:83.
37. Kolde R. pheatmap: Pretty Heatmaps. R
package version 1.0.10 https://cran.r-pro-
ject.org/web/packages/pheatmap/. 2018. 38. Stühmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 path- way as a therapeutic strategy for multiple
myeloma. Blood. 2005;106(10):3609-3617. 39. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-mol- ecule antagonists of MDM2. Science.
2004;303(5659):844-848.
40. Shangary S, Qin D, McEachern D, et al.
dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alterna- tive to TP53 mutation. Blood. 2001;98(3): 814-822.
46. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006;108(3):993-1000.
47. Senturk E, Manfredi JJ. Mdm2 and tumori- genesis: evolving theories and unsolved mysteries. Genes Cancer. 2012;3(3-4):192-
Temporal activation of p53 by a specific
MDM2 inhibitor is selectively toxic to 198.
tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008;105(10):3933-3938.
41. Shangary S, Ding K, Qiu S, et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther. 2008;7(6):1533-1542.
42. Steele AJ, Prentice AG, Hoffbrand AV, et al. p53-mediated apoptosis of CLL cells: evi- dence for a transcription-independent mech- anism. Blood. 2008;112(9):3827-3834.
43. Haidar MA, El-Hajj H, Bueso-Ramos CE, et al. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am J Hematol. 1997;54(3):189-195
44. Konikova E, Kusenda J. Altered expression of p53 and MDM2 proteins in hematologi- cal malignancies. Neoplasma. 2003;50(1):31- 40.
45. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53
48. Petlickovski A, Laurenti L, Li X, et al. Sustained signaling through the B-cell recep- tor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005;105(12):4820-4827.
49. Wyttenbach A, Tolkovsky AM. The BH3- only protein Puma is both necessary and suf- ficient for neuronal apoptosis induced by DNA damage in sympathetic neurons. J Neurochem. 2006;96(5):1213-1226.
50. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and - independent apoptotic pathways. Cancer Cell. 2003;4(4):321-328.
51. Blombery P, Anderson MA, Gong JN, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342-353.
52. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resist- ance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469-1479.
2442
haematologica | 2019; 104(12)